Lennox-Gastaut syndrome rufinamide

Rufinamide is a new triazole derivative with little similarity to other antiseizure drugs. It is approved for use in Lennox-Gastaut syndrome and preliminary evidence suggests that it may also be useful in other difficult-to-treat epilepsy syndromes. 

The data from all clinical trials of rufinamide in patients with Lennox-Gastaut syndrome have been reviewed [272, 273 ]. 

Coppola G, Grosso S, Franzoni E, Veggiotti P, Zamponi N, Paris P, Spalice A, Habetswallner F, Fels A, Capovilla G, Verrotti A, Mangano S, Balestri A, Curatolo P, Pascotto A. Rufinamide in children and adults with Lennox-Gastaut syndrome first Italian multicenter experience. Seizure 2010 19(9) 587-91. 

Placebo-controlled studies The efficacy of rufinamide in Lennox-Gastaut syndrome has been demonstrated in a randomized double-blind clinical trial in 138 patients with highly refractory epilepsy [279 ]. 

Glauser T, Kluger G, Sachdeo R, et al. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 2008 70 1950-8. 

Lee EH, Yum MS, Ko TS. Effectiveness and tolerability of rufinamide in children and young adults with Lennox-Gastaut syndrome a single center study in Korea. Clin Neurol Neurosurg July 2013 115(7) 926-9. 

Rufinamide, a triazole derivative that is structurally distinct from currently marketed antiepUeptic drugs, is a sodium channel blocker in development for the adjunctive treatment in patients with partial seizures and more effective for gen-eraUzed seizures in children with Lennox—Gastaut syndrome, a severe form of childhood epilepsy [142] (Scheme 2.18 and Table 2.15). 

---